Related Party Transactions - Schedule of Allocations for Statements of Operations (Details) - USD ($) $ in Thousands |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2026 |
Jun. 30, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
|
| Related Party Transaction [Line Items] | ||||
| Research and development | $ 25,644 | $ 39,272 | $ 59,599 | $ 80,737 |
| General and administrative | 9,293 | 6,626 | 28,149 | 16,441 |
| Total operating expenses | 34,937 | 45,898 | 87,748 | 97,178 |
| AnaptysBio, Inc. | ||||
| Related Party Transaction [Line Items] | ||||
| Research and development | 1,853 | 13,129 | 17,166 | 26,816 |
| General and administrative | 3,664 | 6,626 | 22,520 | 16,441 |
| Total operating expenses | $ 5,517 | $ 19,755 | $ 39,686 | $ 43,257 |
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|